Skip to main
USPH

USPH Stock Forecast & Price Target

USPH Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

US Physical Therapy is expected to see positive growth in the coming years due to the expanding hospital partnerships, M&A activity, and opening of new clinics. In the first quarter of 2026, the company exceeded revenue expectations and saw a 1.1% increase in salary and related expenses, which is impressive in the current inflationary climate. The industrial injury prevention segment continues to show strong growth, and the company is well-positioned for future expansion through its low debt levels and pursuit of external growth opportunities.

Bears say

US Physical Therapy is facing several challenges, including a missed first quarter result in terms of adjusted EPS, adjusted EBITDA, and cash flows, and concerns over clinician wage pressure as well as Medicare reimbursement pressure. Additionally, the company's exposure to economic contraction, which could decrease demand for their services, and reliance on revenue from industrial injury prevention services for manufacturing customers could negatively impact growth. Furthermore, while they have partnerships with hospital systems, the impact of these partnerships may not be fully realized until 2027. With a recent decline in the company's stock price and a reduction in their price target, it is clear that their profitability estimates have been adjusted and there are uncertainties surrounding the company's future.

USPH has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of U.S. Physical Therapy and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About U.S. Physical Therapy (USPH) Forecast

Analysts have given USPH a Buy based on their latest research and market trends.

According to 4 analysts, USPH has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $98.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $98.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

U.S. Physical Therapy (USPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.